Sign up to save your podcasts
Or
Share Episode 30: Metsera
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 30: Metsera
Send us a text
In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk.
We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company.
If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciences
Support the show
© 2025 Petri Dish Perspectives LLC. All rights reserved.
View all episodes
By Manead KhinSend us a text
In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk.
We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin analogs, became one of the most sought-after assets in metabolic disease. You’ll learn how the bidding unfolded, what the acquisition means for obesity therapeutics, and why Pfizer ultimately paid nearly $10 billion to secure the company.
If you want to understand obesity biotech, GLP-1 strategy, and how a young startup can reshape Big Pharma’s roadmap, this is the episode to hear.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Metsera #Pfizer #NovoNordisk #GLP1 #ObesityDrugs #BiotechPodcast #FlagshipPioneering #DrugDevelopment #PharmaNews #LifeSciences
Support the show
© 2025 Petri Dish Perspectives LLC. All rights reserved.